Patients with cancer could be willing to wait for greater certainty of the benefit of new cancer drugs before they are approved by the U.S. Food and Drug Administration (FDA), suggests a new study from the London School of Economics and Political Science (LSE), published in The Lancet Oncology.
Not all patients want faster cancer drug approvals without certainty they work
-
HighlightsFree Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
HighlightsSmart buildings: What happens to our free will when tech makes choices for us?
-
AppsScreenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
HighlightsDarknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
